Book a demo

Chemical intelligence powered by cypris.ai

Synkavit

tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate · also: Thylokay, Synka-Vit, Synkavite, Synkayvite, Procoagulo, Kappadione

FormulaC11H8Na4O8P2
Mol. weight422.0836
PubChem CID8555
InChIKeyGZBACHSOZNEZOG-UHFFFAOYSA-J
SMILESCC1=C(C2=CC=CC=C2C(=C1)OP(=O)([O-])[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+]
208Patents
94Research papers
6Patents - last 3 years
0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#AssigneePatents
1General Mills Inc33
2Ascendis Pharma AS27
3Firmenich Inc9
4Lineage Cell Therapeutics Inc9
5Aventis Pharmaceuticals Inc6
6Valagro SpA5
7Boston Scientific Corp4
8Avenir Wellness Solutions of California Inc3
9Boston Scientific Scimed Inc3
10Henry H Ottens Manufacturing Co Inc3

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#CodeAreaPatents
1A61KMedicinal preparations151
2A61PTherapeutic activity (drug indications)95
3A23LFoods and beverages (general)47
4A23P35
5Y02AClimate change adaptation30
6A61QCosmetics, personal care29
7A61MDevices for introducing media into the body25
8B01JChemical/physical processes (e.g. catalysts)23
9A21D19
10A23C19

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#Research topicPapers
1Biochemical effects in animals1
2Coenzyme Q10 studies and effects1
3Radiation Effects and Dosimetry1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#AuthorAffiliationPapers
1Ebbe SøndergaardRigshospitalet6
2Henrik DamRigshospitalet5
3G. Hjort4
4H DyggveRigshospitalet4
5H. K. Hanel4
6P. R. Purser4
7D.H. MarrianUniversity of Cambridge3
8E Quagliariello3
9L Peguiron3
10Sigismund Neukomm3

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular composition of Synkavit?

Synkavit has the molecular formula C11H8Na4O8P2 with a molecular weight of 422.0836. Its canonical chemical name is tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate, and it is also known by several alternative names including menadiol sodium diphosphate and menadione sodium phosphate.

Which organizations hold the most patents for Synkavit?

General Mills Inc leads with 33 patents, followed by Ascendis Pharma AS with 27 patents. Other significant patent holders include Firmenich Inc and Lineage Cell Therapeutics Inc, each with 9 patents, and Aventis Pharmaceuticals Inc with 6 patents.

What research areas are associated with Synkavit in the patent literature?

The primary patent classification is A61K (pharmaceutical and medicinal preparations) with 151 patents, followed by A61P (therapeutic activity classification) with 95 patents. Other significant areas include A23L (food composition) with 47 patents and A23P (food preparation) with 35 patents, indicating applications spanning pharmaceuticals, food additives, and therapeutic contexts.

What scientific studies have examined Synkavit or related menadione compounds?

Published research includes a 2006 study on menadione-induced reactive oxygen species generation and apoptosis in pancreatic acinar cells, a 2008 examination of quinone oxidoreductases and vitamin K metabolism, a 1956 clinical study on large doses of Synkavit in newborns, a 1953 comparative study of vitamin K variants in deficient chicks, and a 2005 phase I trial of menadiol diphosphate in advanced malignancy.

How has patent activity for Synkavit evolved in recent years?

Patent activity shows considerable fluctuation over the past decade. Peak years include 2020 with 11 patents and 2017 with 10 patents. Activity in the most recent three years (2022–2024) has declined to 3, 4, and 3 patents respectively, while 2025 shows only 2 patents to date. No new scientific papers have been published in the last three years.

Turn any compound into a complete chemical intelligence landscape

Go beyond static compound data. Cypris resolves identities, patents, papers, and commercial signals into one AI-powered view - so your team can move from a single chemical question to a complete R&D, IP, and market landscape.

Schedule a free trial